FindTrial
Sign In

Cisplatin plus hyperthermia kills Hepg2 cells in intraoperative blood salvage but preserves the function of erythrocytes

Clinical rational blood transfution:a multicentre, open-label study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-OCS-13003599
Enrollment
Unknown
Registered
2013-09-17
Start date
2013-06-05
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cell salvage during tumor surgery

Interventions

chemtherapy group:chemtherapy
heat plus chemtherapy group:heat plus chemtherapy

Sponsors

the Second Affiliated Hospital,School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
23 Years to 81 Years

Inclusion criteria

Inclusion criteria: patients of tumors operation

Exclusion criteria

Exclusion criteria: Patients, with blood disease, diabetes, atherosclerosis or severe hepatopathy, were excluded

Design outcomes

Primary

MeasureTime frame
inhibition rate;cloning formation rate;hemolysis rate;—

Countries

China

Contacts

Public ContactMin Yan

the Second Affiliated Hospital,School of Medicine, Zhejiang University

yanminnina@hotmail.com+86 13757118632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026